| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | Sell | 28,135 | $16.73 | $470,793.59 | -55.0% | +10.5% | +3.9% | |
| May 15, 2024 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 3,000 | $0.15 | $450.00 | +0.1% | - | - | |
| May 15, 2024 | UTHR United Therapeutics Corp | Causey Christopher59 | Director | Sell | 2,000 | $272.90 | $545,800.00 | -32.3% | +18.7% | +11.5% | |
| May 15, 2024 | ETST Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | Buy | 10,000 | $0.15 | $1,500.00 | - | - | - | |
| May 15, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 10,455 | $1.88 | $19,654.35 | -6.5% | +9.3% | +148.4% | |
| May 15, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 40,160 | $272.69 | $10,951,230.40 | -92.7% | +18.7% | +11.5% | |
| May 15, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $270.35 | $1,946,521.95 | -29.4% | +18.7% | +11.5% | |
| May 15, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Quimi Daphne58 | Director | Buy | 5,000 | $1.89 | $9,436.03 | +181.8% | +9.3% | +148.4% | |
| May 15, 2024 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 30,000 | $137.95 | $4,138,435.50 | -32.2% | +6.1% | -15.3% | |
| May 14, 2024 | BCRX Biocryst Pharmaceuticals Inc | Thackray Helen M.78 | Chief R&D Officer | Buy | 30,000 | $5.86 | $175,800.00 | +12.4% | +44.2% | +83.8% | |
| May 14, 2024 | ANIP Ani Pharmaceuticals Inc | Lalwani Nikhil66 | President &CEO | Sell | 16,669 | $66.10 | $1,101,820.90 | -4.2% | -9.6% | -8.6% | |
| May 14, 2024 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 1,310 | $264.35 | $346,298.50 | -100% | +23.7% | +11.1% | |
| May 14, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 150,000 | $0.14 | $20,250.00 | +19.7% | - | - | |
| May 14, 2024 | BCRX Biocryst Pharmaceuticals Inc | Doyle Anthony70 | Chief Financial Officer | Buy | 36,300 | $5.57 | $202,191.00 | +15.8% | +44.2% | +83.8% | |
| May 14, 2024 | COLL Collegium Pharmaceutical, Inc | Bohlin Garen G | Director | Sell | 28,985 | $32.30 | $936,311.15 | -39.3% | +7.0% | -12.7% | |
| May 14, 2024 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 12,500 | $135.63 | $1,695,370.00 | -9.7% | +6.4% | -14.2% | |
| May 14, 2024 | EOLS Evolus, Inc. | Gill David N | Director | Sell | 10,361 | $12.64 | $131,009.60 | -12.2% | +2.2% | -21.8% | |
| May 13, 2024 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 341 | $76.89 | $26,219.49 | -0.5% | +24.1% | +1.4% | |
| May 13, 2024 | EOLS Evolus, Inc. | Malik Vikram54 | Director | Sell | 28,000 | $12.93 | $362,012.00 | -9.9% | +3.5% | -19.7% | |
| May 13, 2024 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 12,016 | $1.26 | $15,140.16 | -1.8% | -4.7% | +92.2% | |
| May 13, 2024 | BCRX Biocryst Pharmaceuticals Inc | Stonehouse Jon P80 | President &CEO | Buy | 30,000 | $5.55 | $166,500.00 | +2.7% | +37.3% | +78.7% | |
| May 13, 2024 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | Chief Legal Officer | Buy | 5,000 | $5.53 | $27,650.00 | +1.7% | +37.3% | +78.7% | |
| May 13, 2024 | BCRX Biocryst Pharmaceuticals Inc | Galson Steven K | Director | Buy | 21,940 | $5.49 | $120,450.60 | +74.1% | +37.3% | +78.7% | |
| May 13, 2024 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 34,840 | $1.26 | $43,898.40 | -4.9% | -4.7% | +92.2% | |
| May 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith49 | Sr. VP, General Counsel &Sec. | Sell | 250 | $67.69 | $16,922.50 | -0.4% | -11.4% | -7.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.